Occam Recruits Former FDA Commissioner to Faeth Therapeutics
In November 2024, Occam recruited Stephen M. Hahn, M.D., to the board of Faeth Therapeutics. Hahn is a CEO-Partner of Flagship Pioneering and Chief Executive Officer of Harbinger Health.
Steve brings two decades of illustrious leadership in healthcare strategy, oncology, and translational/clinical research to this role. From 2019 to 2021, he served as the 24th U.S. Food and Drug Administration (FDA) Commissioner, overseeing COVID and non-COVID regulatory affairs, including therapeutics and vaccine development, devices, diagnostics, and clinical trials.
Before his appointment to the FDA, Steve held the positions of Chief Medical Executive and Chief Operating Officer at the prestigious MD Anderson Cancer Center in Houston. Prior to his executive roles at MD Anderson, he also led the Perelman School of Medicine radiation oncology department at the University of Pennsylvania.
Steve earned his M.D. from Temple University and his B.A. in Biology from Rice University.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.